Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Aip_pax_aav_vegf_tendon
AAV2–VEGF gene therapy for tendon & ligament repair (PAX-001)

One-shot gene therapy at repair—faster, stronger tendon healing than surgery alone.

RIH-origin patents + ~$1.7M seed + RILSH LIFT for IND—physician-chairman Liu MD with pre-IND complete.

Entity: Pax TherapeuticsPatents: 1Stage: preclinical ind enabling
WO2019146830A1Source
Open dossier
Tier APatent gapgap_rih_motile_cell_msk
Motile injectable cell for MSK repair (RIH)

Motile injectable cell therapy to accelerate meniscus and connective-tissue repair.

NIAMS R01AR080726 + R21AR077326 (Jayasuriya); large-animal next gate.

Patents: 1Stage: preclinical grant
WO2025155768A1R01AR080726R21AR077326PMID 36312551PMID 39763468
Open dossier
Tier APatent gapgap_rih_ecm_joint_repair
Biomimetic ECM for joint tissue repair (RIH)

Biomimetic ECM reconstitution for musculoskeletal joint repair.

Field-of-use diligence vs XM Therapeutics before Slater-scale spinout.

Patents: 1Stage: preclinical grant
US20240139376A1R01AR080726R21AR077326PMID 29542287
Open dossier
Tier APatent gapgap_rih_lpa_therapeutic
Lp(a)-lowering therapeutic approach (RIH)

RIH therapeutic approach to lower lipoprotein(a)—cardiovascular metabolic niche.

Differentiate vs Phase 3 siRNA/antisense leaders; Song lab R01HL159204 anchors cardio lipid biology.

Patents: 1Stage: preclinical grant
WO2025245119A1R01HL159204
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.